Nektar Therapeutics announced on October 3, 2023, that its experimental drug, known as rezpeg, demonstrated significant effectiveness in treating moderate-to-severe eczema, also referred to as atopic dermatitis, during a one-year study. The results revealed that 71% of patients receiving monthly injections and 83% of those receiving quarterly injections maintained substantial improvements in skin lesions after 12 months.
The findings from this maintenance study not only met but, in some cases, surpassed expectations among investors and industry analysts. This positions rezpeg as a formidable contender in the eczema treatment market, particularly against leading biologics like Dupixent and Ebglyss, which are currently the most commonly prescribed treatments for the condition.
Comparative Efficacy and Treatment Frequency
Mary Tagliaferri, Chief Medical Officer at Nektar Therapeutics, emphasized the competitive edge of their drug in an interview with STAT. She stated, “When you compare our results competitively, we’re showing better efficacy with less frequent injections.” This highlights a significant advantage, as patients often prefer treatment options that require fewer administration sessions.
The findings are particularly noteworthy given the chronic nature of eczema, a condition that affects millions worldwide and can lead to severe discomfort and impacted quality of life. Current treatment options often come with a regimen that demands frequent doses, making rezpeg’s less frequent injection schedule appealing.
Future Implications for Eczema Treatment
The promising results from Nektar Therapeutics come at a crucial time as the demand for effective and convenient treatments for eczema continues to grow. With the skin condition affecting approximately 10% of children and 3% of adults, the potential market for an effective drug like rezpeg could be substantial.
As the pharmaceutical landscape evolves, the competition among eczema treatments is likely to intensify. With rezpeg now in the conversation, healthcare providers may have a new option to consider when prescribing treatment for patients suffering from this debilitating condition.
Nektar plans to submit these results to regulatory authorities as part of their ongoing efforts to bring rezpeg to market. The company remains optimistic about the drug’s potential to improve patient outcomes and offer a new hope for those living with eczema.
